Patents by Inventor Timo Heinrich

Timo Heinrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide
    Patent number: 12378225
    Abstract: A process can be used for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: August 5, 2025
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Jeyaprakashnarayanan Seenisamy
  • Disubstituted alkyne derivatives
    Patent number: 12351570
    Abstract: The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 8, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Carl Petersson, Mireille Krier, Andrzej Gondela, Michal Mikolaj Galezowski, Charles-Henry Robert Yves Fabritius, Mateusz Oktawian Nowak, Marcin Krol
  • HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS
    Publication number: 20250032625
    Abstract: Compounds of the formula (I) Q1-Q2-Q3 (I) in which Q1, Q2 and Q3 have the meanings indicated in claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases and conditions mediated by such target proteins.
    Type: Application
    Filed: October 31, 2022
    Publication date: January 30, 2025
    Inventors: Timo HEINRICH, Paul Gehrtz
  • SRPK INHIBITORS
    Publication number: 20240382481
    Abstract: Compounds of formula (I) are made, wherein W1, W2, W3, W4, R1, R2, R3, R4, R5, R6 and m have the meaning as described herein. The compounds are SRPK inhibitors and can be used, inter alia, for the treatment of hyperproliferative disorders. A medicament and a pharmaceutical composition are made that include the compound of formula (I). Methods are developed for treating a disease caused, mediated, and/or propagated by SRPK activity, for preparing a medicament for the treatment thereof, and for inhibiting SRPK.
    Type: Application
    Filed: July 28, 2022
    Publication date: November 21, 2024
    Applicant: Merck Patent GmbH
    Inventors: Matthias Leiendecker, Timo Heinrich
  • Tricyclic heterocycles
    Publication number: 20240317753
    Abstract: Tricyclic heterocycles are disclosed. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.
    Type: Application
    Filed: May 5, 2021
    Publication date: September 26, 2024
    Applicants: Merck Patent GmbH, Cancer Research Technology Ltd.
    Inventors: Timo HEINRICH, Sarah Schlesiger, Jakub Gunera, Emma Carswell, Lisa Koetzner, Andreas Blum
  • TRICYCLIC HETEROCYCLES
    Publication number: 20240270748
    Abstract: Tricyclic heterocycles are useful as TEAD binders and/or inhibitors of YAP-TEAD. Tricyclic heterocycles can be used for TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.
    Type: Application
    Filed: November 2, 2021
    Publication date: August 15, 2024
    Applicants: Merck Patent GmbH, Cancer Research Technology Ltd.
    Inventors: Timo Heinrich, Sarah Schlesiger, Jakub Gunera, Lisa Koetzner, Emma Carswell, Andreas Blum
  • TRICYCLIC HETEROCYCLES
    Publication number: 20230278958
    Abstract: The tricyclic heterocycles disclosed herein are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.
    Type: Application
    Filed: July 20, 2021
    Publication date: September 7, 2023
    Applicants: Merck Patent GmbH, Cancer Research Technology Ltd.
    Inventors: Timo Heinrich, Sarah Schlesiger, Jakub Gunera, Lisa Koetzner, Emma Carswell, Andreas Blum
  • Tricyclic heterocycles
    Publication number: 20230174538
    Abstract: Tricyclic heterocycles are disclosed. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.
    Type: Application
    Filed: May 5, 2021
    Publication date: June 8, 2023
    Applicants: Merck Patent GmbH, Cancer Research Technology Ltd.
    Inventors: Timo HEINRICH, Sarah Schlesiger, Jakub Gunera, Emma Carswell, Lisa Koetzner, Andreas Blum
  • DISUBSTITUTED ALKYNE DERIVATIVES
    Publication number: 20230052586
    Abstract: The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 16, 2023
    Inventors: Timo Heinrich, Carl Petersson, Mireille Krier, Andrzej Gondela, Michal Mikolaj Galezowski, Charles-Henry Robert Yves Fabritius, Mateusz Oktawian Nowak, Marcin Krol
  • Process for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide
    Publication number: 20220251072
    Abstract: A process can be used for manufacturing (S)-3-hydroxy-1-(1H-indol-5-yl)-2-oxo-pyrrolidine-3-carboxylic acid 3,5-difluoro-benzylamide.
    Type: Application
    Filed: June 30, 2020
    Publication date: August 11, 2022
    Applicant: Merck Patent GmbH
    Inventors: Timo Heinrich, Jeyaprakashnarayanan Seenisamy
  • Heterocyclic derivatives
    Publication number: 20220062258
    Abstract: Compounds of the formula I Q1-Q2-Q3??I corresponding to E3 ligase binding compounds can degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: January 20, 2020
    Publication date: March 3, 2022
    Applicant: Merck Patent GmbH
    Inventors: Timo Heinrich, Sarah Schlesiger
  • Cyclic amides as MetAP-2 inhibitors
    Patent number: 10093623
    Abstract: Described are cyclic amide compounds of the formula (I): in which R1, R3, R5, R6, R7, R, X and Y have the meanings as described. The compounds are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: October 9, 2018
    Assignee: MERCK PATENT GmbH
    Inventors: Timo Heinrich, Frank Zenke, Mireille Krier, Manja Friese-Hamim, Jeyaprakashnarayanan Seenisamy
  • Pyrrolidinone derivatives as MetAP-2 inhibitors
    Patent number: 10005756
    Abstract: Compounds according to Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: June 26, 2018
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Frank Zenke, Felix Rohdich, Manja Friese-Hamim, Diane Hahn
  • PYRIMIDINE DERIVATIVES
    Publication number: 20180118721
    Abstract: Compounds of Formula I or II in which R1, X1 and X2 have the meanings indicated in claim 1, are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.
    Type: Application
    Filed: February 12, 2016
    Publication date: May 3, 2018
    Applicant: Merck Patent GmbH
    Inventors: Timo HEINRICH, Ulrich PEHL
  • PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS
    Publication number: 20170226080
    Abstract: Compounds according to Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: July 10, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Timo HEINRICH, Frank ZENKE, Felix ROHDICH, Manja FRIESE-HAMIM, Diane HAHN
  • Bicyclic heteroaromatic compounds
    Patent number: 9249140
    Abstract: Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: February 2, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Felix Rohdich, Christina Esdar, Mireille Krier, Hartmut Greiner
  • 1-H-pyrrolo[2,3-b]pyridine derivatives
    Patent number: 9238651
    Abstract: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: January 19, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller
  • Substituted azaheterocycles for the treatment of cancer
    Patent number: 9199962
    Abstract: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: December 1, 2015
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Nadia Brugger, Kristopher Josephson
  • BICYCLIC HETEROAROMATIC COMPOUNDS
    Publication number: 20150218155
    Abstract: Compounds of the formula I, in which X1, X2, X3, X4, X5, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Claim 1, are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 6, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Timo Heinrich, Felix Rohdich, Christina Esdar, Mireille Krier, Hartmut Greiner
  • 7-azaindole derivatives suitable for treatment of cancers
    Patent number: 8993564
    Abstract: Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed treatment of tumours.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller